Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | RAB9A | P51151 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31175292 | 0.88 | SMN1; SMN2 (0.71) | TP53SMN1; SMN2KMT2AMEN1LMNA | |
| SCHEMBL939911 | 0.88 | SMN1; SMN2 (0.71) | TP53SMN1; SMN2KMT2AMEN1LMNA | |
| SCHEMBL334915 | 0.87 | TP53 (0.71) | TP53SMN1; SMN2KMT2AMEN1LMNA | |
| SCHEMBL7826388 | 0.85 | TP53 (0.60) | TP53SMN1; SMN2KMT2AMEN1LMNA | |
| Hydrochloric Acid SCHEMBL7826167 | 0.84 | TP53 (0.59) | TP53SMN1; SMN2KMT2AMEN1LMNA | |
| SCHEMBL21152328 | 0.83 | NOTUM (0.72) | TP53SMN1; SMN2KMT2AMEN1LMNA | |
| SCHEMBL8700331 | 0.82 | SMN1; SMN2 (0.67) | TP53SMN1; SMN2KMT2AMEN1LMNA | |
| Hydrochloric Acid SCHEMBL8706081 | 0.81 | SMN1; SMN2 (0.66) | TP53SMN1; SMN2KMT2AMEN1LMNA | |
| SCHEMBL3328195 | 0.80 | KCNJ1 (0.71) | KMT2ALMNANOTUMRAB9A | |
| SCHEMBL30010532 | 0.80 | NOTUM (0.61) | TP53SMN1; SMN2KMT2AMEN1EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663204-B1 | C-KIT MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2014-05-07 | — | — | EP | disclosed |
| US-8362017-B2 | N-[5-chloro-2-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide; antiproliferative agents; protein kinase inhibitors; drug screening | EXELIXIS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362017-B2 | N-[5-chloro-2-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide; antiproliferative agents; protein kinase inhibitors; drug screening | EXELIXIS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8362017-B2 | N-[5-chloro-2-(methyloxy)phenyl]-2-{[3-(1H-tetrazol-1-yl)phenyl]oxy}acetamide; antiproliferative agents; protein kinase inhibitors; drug screening | EXELIXIS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20080096892-A1 | C-Kit Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080096892-A1 | C-Kit Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080096892-A1 | C-Kit Modulators And Methods Of Use | EXELIXIS, INC. (US) | 2008-04-24 | — | — | US | disclosed |
| CN-1143856-C | Novel substituted N-methyl-N-(4-(4-(1H-benzimidazol-2-yl) [1,4] diazepan-1-yl)-1-(aryl) butyl) benzamides useful for treatment of allergic diseases | ���µ�˹ҩ�﹫˾ | 2004-03-31 | — | — | CN | disclosed |
| CN-1136191-C | Carboxy substituted carboxamide derivatives as tachykinin receptor antagonists | ������ҩ������˾ | 2004-01-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080096892-A1 | C-Kit Modulators And Methods Of Use | KIT, PRKCH, PRKCB | TP53 1271/4885SMN1; SMN2 3206/4885KMT2A 1897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.